Milestones in Chronic Myeloid Leukemia
An article on targeted therapy for chronic myeloid leukemia by Brian Druker, MD, and these accompanying milestones were published in December 2008 as part of the special ASH anniversary brochure, 50 Years in Hematology: Research That Revolutionized Patient Care.
| 1845 | John Hughes Bennett and Rudolph Virchow describe the first cases of CML. |
| 1960 | Peter Nowell and David Hungerford identify an abnormal chromosome in the blood cells and bone marrow of patients with CML. |
| 1973 | Janet Rowley determines that the abnormal chromosome identified by Nowell and Hungerford results from the exchange of genetic material between two chromosomes. |
| 1982- 1985 |
John Groffen, Nora Heisterkamp, Gerard Grosveld, E. Cannani, David Baltimore, and Owen Witte show that an abnormal gene and protein called BCR-ABL is produced as a consequence of the chromosome rearrangement that characterizes CML. |
| 1987 | Nicholas Lydon and Alex Matter begin a drug discovery program to target proteins such as BCR-ABL in collaboration with Brian Druker, Thomas Roberts, and Charles Stiles. |
| 1993 | Brian Druker's laboratory shows that STI571 (imatinib) is the best of the compounds developed by Nicholas Lydon's group at specifically targeting and killing CML cells. |
| 1998 | Brian Druker, Charles Sawyers, and Moshe Talpaz begin clinical trials of imatinib. |
| 2001 |
Imatinib is FDA-approved for patients with CML. |
| Charles Sawyers, Brian Druker, Andreas Hochhaus, and François-Xavier Mahon report that mutations of BCR-ABL are the major mechanism of resistance to imatinib. | |
| 2006 | Follow-up data show a 95 percent five-year survival for patients with CML treated with imatinib. |
| 2006,2007 |
Dasatinib and nilotinib are FDA-approved for patients with imatinib resistance. |
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission